Company Overview and News

 
There’s money to be made in land reclamation

2018-09-01 thestar.com.my
Getting bigger : Land reclamation works of Seri Tanjung Pinang Phase Two at Tanjung Tokong. The area of reclaimed land in Penang island is expected to be about 7,981 acres in the coming years.
5190

1
Giant dredger sailing between Johor and Singapore on sand smuggling route

2018-06-28 malaymail
JOHOR BARU, June 28 — For the past one month, a titanic Dutch sand dredger dubbed the “world’s largest floating vacuum cleaner” has been spotted sailing back-and-forth between Johor and southern Singapore along a sea route well known for its smuggling activity.
5190

5
Trading ideas: Construction stocks, Eduspec, Benalec, UEM Edgenta, PPB

2018-05-14 thestar.com.my
KUALA LUMPUR: JF Apex Research expects construction stocks, Eduspec holdings Bhd , Benalec Holdings Bhd, UEM Edgenta Bhd and PPB Group Bhd to be among the stocks to watch on Monday.
5190 1368 4065

1
Trading ideas: Fitters Diversified, Datasonic, Cypark, Benalec, CCK

2018-04-12 thestar.com.my
KUALA LUMPUR: JF Apex Research expects Fitters Diversified Bhd , Datasonic Group Bhd , Cypark Resources Bhd , Benalec Holdings Bhd and CCK Consolidated Holdings Bhd to be among the stocks to watch on Thursday.
5190 5216 9318 5184 7035

5
Benalac to undertake private placement

2018-04-11 thestar.com.my
PETALING JAYA: Construction outfit Benalec Holdings Bhd plans to undertake a private placement exercise to raise funds primarily for its ongoing and future land reclamation projects.
5190 BSMAF 1818

5
Benalec to place out RM31.4mil new shares

2018-04-11 thestar.com.my
KUALA LUMPUR: Benalec Holdings Bhd is planning to raise as much as RM31.4mil by placing out new shares in the company to third party investors it will identify at a later date.
5190 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...